Modules
Silverline Clinical Group, Inc.
Customer 8342
- Account Classification
- End-User Laboratory
- Classification Confidence
- High
- Sites
- HQ | Vendor | 1942f88c4d2a4bf16d1131c29ee602dcef5195e9fa23eeb48ca852b8efd58e2b
- Assigned Reps
- Raymond Sutter
- Website
- —
- Active Opportunity Count
- 12
- Published Count
- 5
- Revenue Base
- 8257.19
- Known GPBase
- 2584.68
- Analyzer Platforms
- Beckman Access / DxI | Olympus / Beckman AU
- Product Groups
- Beckman Access | Olympus | Parts Group
- Recommended Contact
- Kara Kessler
- Backup Contact
- Jenna Abrams |
- Last Meaningful Activity
- 2026-03-19
- Customer Memory
- Verified transaction fact: platform/product group signal is Beckman Access / DxI. Verified item fact: storage requirement N/A. Rep-entered/customer record note: shipping notes exist; verify details before shipment. AI inference: opportunity is based on deterministic order/quote pattern and requires normal rep validation during outreach. Verified item fact: storage requirement N/A. Rep-entered/customer record note: shipping notes exist; verify details before shipment. AI inference: opportunity is based on deterministic order/quote pattern and requires normal rep validation during outreach. Verified transaction fact: platform/product group signal is Beckman Access / DxI. Verified item fact: storage requirement Fridge. Rep-entered/customer record note: shipping notes exist; verify details before shipment. AI inference: opportunity is based on deterministic order/quote pattern and requires normal rep validation during outreach. Rep-entered/customer record note: shipping notes exist; verify details before shipment. AI inference: opportunity is based on deterministic order/quote pattern and requires normal rep validation during outreach.
- Evidence References
- Candidate CAND-ecbc3df26074aef343eed0e19e4cf0a22fd95b8b52c430d075d722fb3b83e534 | Customer 8342 | Item 4880 | Candidate CAND-6f5c590e43d112df2ecee77def2fa174e571b390bad76fb5cf4b263ed52c838f | Customer 8342 | Quote 24195 | Item 12342 | Candidate CAND-4a11cee94f2c3541d9702d92d6aba4929a1ef9783190187d95cf4e9d3dbc5058 | Customer 8342 | Order 51213 | Item 4265 | Candidate CAND-24058a69041f0b6a163b8e512968f5c6fb4663eb9d81fbd66d811a2769683701 | Customer 8342 | Candidate CAND-083209304f0b85419e9b6975592689105fadd76cb3d4984fd630a9cffbcd9345 | Customer 8342 | Order 46493 | Item 4252
Opportunities (18)
| Source Sheet | Report Run ID | Candidate ID | Opportunity ID | Opportunity Series ID | Final Disposition | Assigned Rep | Territory Rep | Source Rep | Customer | Customer ID | Site | City | State | Region | Account Classification | Classification Confidence | Analyzer Platform | Product Group | SKU | Item Description | Quote Doc No | Order Doc No | Deterministic Signal | Revenue Low | Revenue Base | Revenue High | GP Low | GP Base | GP High | Priority Score | Confidence | Open Order | Open Quote | Suppression Status | Next Best Action | Evidence Reference |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Account Risk | 234b565c-29e5-43bb-9356-74dd911ab649 | CAND-b9d4d8abd4b62f7c88c34d93f49f5e57072d533651156797ba5dccee4c31eb31 | OPP-79f4756e7f183c5c552545505a268a821d289329773e173304fcb9f47515a58b | SER-c88ffb1a9a09373d7581c1039661c1eb5857fdae20b2fd2a615bb1289792d07c | Suppressed by Open Order | **** | **** | **** | Silverline Clinical Group, Inc. | 8342 | HQ | Edison | NJ | Northeast | End-User Laboratory | High | — | — | — | — | — | — | Reduced Order Frequency; 2 independent signals; trailing 90-day revenue $38238.00 versus $56803.00; trailing 180-day revenue $95041.00 versus $76223.05; 4 days beyond expected account order date. | 9282.5 | 18565.01 | 27847.51 | 3558.34 | 7116.68 | 10675.03 | 82.04 | Medium | True | True | Open Order | MANAGER_REVIEW | Candidate CAND-b9d4d8abd4b62f7c88c34d93f49f5e57072d533651156797ba5dccee4c31eb31 | Customer 8342 |
| Account Risk | 234b565c-29e5-43bb-9356-74dd911ab649 | CAND-24058a69041f0b6a163b8e512968f5c6fb4663eb9d81fbd66d811a2769683701 | OPP-857e538fb6add0aeb75a4d489dfa810b0351492b52b44daa5a241c214d1f428b | SER-0e8abff944c0566e77ac1aadfb6f362042f52ad455fe9cba529683d8f5936fde | Published | **** | **** | **** | Silverline Clinical Group, Inc. | 8342 | Vendor | Edison | NJ | Northeast | End-User Laboratory | High | — | — | — | — | — | — | Materially Delayed Purchasing; 3 independent signals; trailing 90-day revenue $0.00 versus $1051.00; trailing 180-day revenue $1051.00 versus $1527.51; 118 days beyond expected account order date. | 525.5 | 1051 | 1576.5 | 136.42 | 272.83 | 409.25 | 70.55 | Medium | False | True | — | CALL | Candidate CAND-24058a69041f0b6a163b8e512968f5c6fb4663eb9d81fbd66d811a2769683701 | Customer 8342 |
| Overdue Reorders | 234b565c-29e5-43bb-9356-74dd911ab649 | CAND-ab0162930b931f5e618a012b67f76fb1bce144d1ddb5f9b174e425d4dfb23ae9 | OPP-9a6cba1325d493816b8db517ec7d2769a062ae7992a3d960eb7faccb13a94ea9 | SER-3cb773ce15cb6fa745d22140e9d2e6af3f872366eea6d82756b569c007e28997 | Needs Validation | **** | **** | **** | Silverline Clinical Group, Inc. | 8342 | HQ | Edison | NJ | Northeast | End-User Laboratory | High | Beckman Access / DxI | Beckman Access | 37200 | 37200 Beckman ACCESS PSA HYBRTECH RGT 100S | — | 51213 | 13 completed purchases over 846 days; median interval 28.5 days; expected reorder 2026-05-13; High Risk by 89 days. | 1181.25 | 1575 | 1968.75 | 362.25 | 483 | 603.75 | 76.61 | Low | False | False | — | MANAGER_REVIEW | Candidate CAND-ab0162930b931f5e618a012b67f76fb1bce144d1ddb5f9b174e425d4dfb23ae9 | Customer 8342 |
| Overdue Reorders | 234b565c-29e5-43bb-9356-74dd911ab649 | CAND-4a11cee94f2c3541d9702d92d6aba4929a1ef9783190187d95cf4e9d3dbc5058 | OPP-ce6e599dfc18eeb0ceb524e48fbde3cbb70d35c4472a23d8ac1428ccd10af62c | SER-35b0754039084377efbdcd3200b7259abd65f554750221318ef3295aad3575eb | Published | **** | **** | **** | Silverline Clinical Group, Inc. | 8342 | HQ | Edison | NJ | Northeast | End-User Laboratory | High | Beckman Access / DxI | Beckman Access | 37210 | 37210 BECKMAN ACCESS PSA HYBRTCH FREE 100S - Discounted from $135 to $105.82 to account for discount we agreed on | — | 51213 | 10 completed purchases over 689 days; median interval 49.0 days; expected reorder 2026-05-28; High Risk by 74 days. | 956.25 | 1275 | 1593.75 | 303.75 | 405 | 506.25 | 76.24 | Medium | False | False | — | CALL | Candidate CAND-4a11cee94f2c3541d9702d92d6aba4929a1ef9783190187d95cf4e9d3dbc5058 | Customer 8342 | Order 51213 | Item 4265 |
| Overdue Reorders | 234b565c-29e5-43bb-9356-74dd911ab649 | CAND-446902eda0f2998554dbe8ffe8bedf4baa3651a632879c8b473a56dc58408a47 | OPP-e2b301d912ac21234743876122d72da1f984ccfb1fd04c9e54e724c038d55fcc | SER-e7653b221da911be98dc5b98ef5151f26b27a51e08550c77d5272e31d32ee543 | Needs Validation | **** | **** | **** | Silverline Clinical Group, Inc. | 8342 | HQ | Edison | NJ | Northeast | End-User Laboratory | High | Beckman Access / DxI | Beckman Access | A13422 | A13422 T3 FREE RGT 100/BX | — | 51923 | 14 completed purchases over 987 days; median interval 28.0 days; expected reorder 2026-06-03; High Risk by 68 days. | 682.5 | 910 | 1137.5 | 315 | 420 | 525 | 75.8 | Low | False | False | — | MANAGER_REVIEW | Candidate CAND-446902eda0f2998554dbe8ffe8bedf4baa3651a632879c8b473a56dc58408a47 | Customer 8342 |
| Overdue Reorders | 234b565c-29e5-43bb-9356-74dd911ab649 | CAND-78f7b8e331ee42ff2eb35a12d1efd5d795d9709754785468d63d4103b532e4fe | OPP-59e6c767078aab7deea30f881131b2101df4d1ebad613f37bacd41d41bc56851 | SER-5cc62d6ead5e5b949bb2a36bd220090a044a9e983e7e676ac7626fe8ddd85f71 | Needs Validation | **** | **** | **** | Silverline Clinical Group, Inc. | 8342 | HQ | Edison | NJ | Northeast | End-User Laboratory | High | Beckman Access / DxI | Beckman Access | A12985 | A12985 TPO Antibody, Access, 2 x 50 tests - MUST ALL BE SAME LOT | — | 51425 | 12 completed purchases over 759 days; median interval 35.0 days; expected reorder 2026-06-15; High Risk by 56 days. | 725 | 966.67 | 1208.33 | 178.69 | 238.25 | 297.81 | 74.56 | Low | False | False | — | MANAGER_REVIEW | Candidate CAND-78f7b8e331ee42ff2eb35a12d1efd5d795d9709754785468d63d4103b532e4fe | Customer 8342 |
| Overdue Reorders | 234b565c-29e5-43bb-9356-74dd911ab649 | CAND-4051d8fb44a0663af05acfcaef46f3e7448036525f64c16678dc09cc3e4bd6ee | OPP-3a17740af407eb6a39c603d91c9f92a5f972cd71b203b5398c638b32306e1356 | SER-692c6133e3f06d96d1751b26e2081a613e5ef4f11bf9096bd0d29d79786a580c | Needs Validation | **** | **** | **** | Silverline Clinical Group, Inc. | 8342 | HQ | Edison | NJ | Northeast | End-User Laboratory | High | Beckman Access / DxI | Beckman Access | 33560 | 33560 Beckman Access Testosterone (REF) | — | 51213 | 11 completed purchases over 861 days; median interval 27.5 days; expected reorder 2026-05-19; High Risk by 83 days. | 368.75 | 491.67 | 614.58 | 138.75 | 185 | 231.25 | 70.87 | Low | False | False | — | MANAGER_REVIEW | Candidate CAND-4051d8fb44a0663af05acfcaef46f3e7448036525f64c16678dc09cc3e4bd6ee | Customer 8342 |
| Overdue Reorders | 234b565c-29e5-43bb-9356-74dd911ab649 | CAND-083209304f0b85419e9b6975592689105fadd76cb3d4984fd630a9cffbcd9345 | OPP-b592309e6fc8d279dba0a262ebb64769c321bd245cb0ddf7a9dc0be81e685a09 | SER-484eebf9989b35ecb0504f1cf01be7a48e3b2024af678320e91e30cca8d47d16 | Published | **** | **** | **** | Silverline Clinical Group, Inc. | 8342 | HQ | Edison | NJ | Northeast | End-User Laboratory | High | Beckman Access / DxI | Beckman Access | 33800 | 33800 BECKMAN ACCESS TOTAL T4 RGT 100/BX | — | 46493 | 5 completed purchases over 626 days; median interval 188.0 days; expected reorder 2026-01-01; High Risk by 221 days. | 454.75 | 606.33 | 757.92 | 59.25 | 79 | 98.75 | 64.82 | Medium | False | False | — | CALL | Candidate CAND-083209304f0b85419e9b6975592689105fadd76cb3d4984fd630a9cffbcd9345 | Customer 8342 | Order 46493 | Item 4252 |
| Overdue Reorders | 234b565c-29e5-43bb-9356-74dd911ab649 | CAND-b22bbff6a9935ea4842b2571373d19c7b0fd4fd96fe7238c35eb38d27b39ce91 | OPP-4478ef97cd63aadb3f12500019ed93e44272fcaf248ce41f24938ff558f305fc | SER-2a8adfc76f78b1c6482c9a7abce9d6bb7e1673bc01d69e85a725a1b7f612d68b | Needs Validation | **** | **** | **** | Silverline Clinical Group, Inc. | 8342 | HQ | Edison | NJ | Northeast | End-User Laboratory | High | Olympus / Beckman AU | Olympus | OSR60118 | OSR60118 Triglycerides reagent 4x20/4x5mL 4/Kt | — | 50564 | 7 completed purchases over 876 days; median interval 59.5 days; expected reorder 2026-05-11; High Risk by 91 days. | 118.5 | 158 | 197.5 | 18.75 | 25 | 31.25 | 63.62 | Low | False | False | — | MANAGER_REVIEW | Candidate CAND-b22bbff6a9935ea4842b2571373d19c7b0fd4fd96fe7238c35eb38d27b39ce91 | Customer 8342 |
| Overdue Reorders | 234b565c-29e5-43bb-9356-74dd911ab649 | CAND-3918fcef18e2203f8a4d6b5e513255c26b5077858b6004ea80e7697d0a47273a | OPP-60a94a62714a0fc311e8b442c0fb47639eb6d4b2b19dcd8ec1307ad5265c2d9a | SER-b09f1c6bd36e2a0f123dd2b67fee589dec3af9583993967cb8fbac2cc7caa53a | Needs Validation | **** | **** | **** | Silverline Clinical Group, Inc. | 8342 | HQ | Edison | NJ | Northeast | End-User Laboratory | High | Beckman Access / DxI | Beckman Access | 33020 | 33020 BECKMAN ACCESS FERRITIN RGT 100/BX | — | 53251 | 12 completed purchases over 1067 days; median interval 44.0 days; expected reorder 2026-09-06; Due Soon in 27 days. | 957.75 | 1277 | 1596.25 | 133.59 | 178.13 | 222.66 | 63.57 | Low | False | False | — | MANAGER_REVIEW | Candidate CAND-3918fcef18e2203f8a4d6b5e513255c26b5077858b6004ea80e7697d0a47273a | Customer 8342 |
| Quote Leakage | 234b565c-29e5-43bb-9356-74dd911ab649 | CAND-6f5c590e43d112df2ecee77def2fa174e571b390bad76fb5cf4b263ed52c838f | OPP-19e7543735e8d9e7d139f01fe0be47240d041e131bbb9e021fabbbe2ceefd712 | SER-60456419486a1e14ae5020a0db85daaf1c79b687d974528feb66570e920c7b6f | Published | **** | **** | **** | Silverline Clinical Group, Inc. | 8342 | — | Edison | NJ | Northeast | End-User Laboratory | High | — | Parts Group | Roche-Cobas-E411-R | Roche Cobas E411, Refurbished - Including 90 day warranty | 24195 | — | Stale Open Quote on quote 24195; quote age 592 days; last modified 591 days ago; quoted value $25000.00; converted line value $0.00; unconverted line value $25000.00. | 2500 | 5000 | 7500 | 877.5 | 1755 | 2632.5 | 80.83 | Medium | False | True | — | RESEND_QUOTE | Candidate CAND-6f5c590e43d112df2ecee77def2fa174e571b390bad76fb5cf4b263ed52c838f | Customer 8342 | Quote 24195 | Item 12342 |
| Cross-Sell | 234b565c-29e5-43bb-9356-74dd911ab649 | CAND-ecbc3df26074aef343eed0e19e4cf0a22fd95b8b52c430d075d722fb3b83e534 | OPP-47e724027f8cd94ccf64084c184d626ad1bb0bd00aa94ab39938cd1c82a91303 | SER-bbb24624bec4cec01795e61d4538bf1dab5c6d089a795bd1aeb045f0d94afd51 | Published | **** | **** | **** | Silverline Clinical Group, Inc. | 8342 | HQ | Edison | NJ | Northeast | End-User Laboratory | High | Beckman Access / DxI | Beckman Access | 81901 | 81901 Beckman Access Cuvette Reaction Vessels | — | — | Verified by Description for Beckman Access / DxI; item purchased by 16 of 40 comparable active sites (40.0%); peer median annual revenue $324.86. | 162.43 | 324.86 | 487.29 | 36.43 | 72.85 | 109.28 | 61.26 | High | False | False | — | CONFIRM_ANALYZER | Candidate CAND-ecbc3df26074aef343eed0e19e4cf0a22fd95b8b52c430d075d722fb3b83e534 | Customer 8342 | Item 4880 |
| Needs Validation | 234b565c-29e5-43bb-9356-74dd911ab649 | CAND-ab0162930b931f5e618a012b67f76fb1bce144d1ddb5f9b174e425d4dfb23ae9 | OPP-9a6cba1325d493816b8db517ec7d2769a062ae7992a3d960eb7faccb13a94ea9 | SER-3cb773ce15cb6fa745d22140e9d2e6af3f872366eea6d82756b569c007e28997 | — | **** | — | — | Silverline Clinical Group, Inc. | 8342 | HQ | — | NJ | — | — | — | Beckman Access / DxI | — | — | — | — | — | 13 completed purchases over 846 days; median interval 28.5 days; expected reorder 2026-05-13; High Risk by 89 days. | — | 1575 | — | — | 483 | — | 76.61 | Low | — | — | — | MANAGER_REVIEW | Candidate CAND-ab0162930b931f5e618a012b67f76fb1bce144d1ddb5f9b174e425d4dfb23ae9 | Customer 8342 |
| Needs Validation | 234b565c-29e5-43bb-9356-74dd911ab649 | CAND-446902eda0f2998554dbe8ffe8bedf4baa3651a632879c8b473a56dc58408a47 | OPP-e2b301d912ac21234743876122d72da1f984ccfb1fd04c9e54e724c038d55fcc | SER-e7653b221da911be98dc5b98ef5151f26b27a51e08550c77d5272e31d32ee543 | — | **** | — | — | Silverline Clinical Group, Inc. | 8342 | HQ | — | NJ | — | — | — | Beckman Access / DxI | — | — | — | — | — | 14 completed purchases over 987 days; median interval 28.0 days; expected reorder 2026-06-03; High Risk by 68 days. | — | 910 | — | — | 420 | — | 75.8 | Low | — | — | — | MANAGER_REVIEW | Candidate CAND-446902eda0f2998554dbe8ffe8bedf4baa3651a632879c8b473a56dc58408a47 | Customer 8342 |
| Needs Validation | 234b565c-29e5-43bb-9356-74dd911ab649 | CAND-78f7b8e331ee42ff2eb35a12d1efd5d795d9709754785468d63d4103b532e4fe | OPP-59e6c767078aab7deea30f881131b2101df4d1ebad613f37bacd41d41bc56851 | SER-5cc62d6ead5e5b949bb2a36bd220090a044a9e983e7e676ac7626fe8ddd85f71 | — | **** | — | — | Silverline Clinical Group, Inc. | 8342 | HQ | — | NJ | — | — | — | Beckman Access / DxI | — | — | — | — | — | 12 completed purchases over 759 days; median interval 35.0 days; expected reorder 2026-06-15; High Risk by 56 days. | — | 966.67 | — | — | 238.25 | — | 74.56 | Low | — | — | — | MANAGER_REVIEW | Candidate CAND-78f7b8e331ee42ff2eb35a12d1efd5d795d9709754785468d63d4103b532e4fe | Customer 8342 |
| Needs Validation | 234b565c-29e5-43bb-9356-74dd911ab649 | CAND-4051d8fb44a0663af05acfcaef46f3e7448036525f64c16678dc09cc3e4bd6ee | OPP-3a17740af407eb6a39c603d91c9f92a5f972cd71b203b5398c638b32306e1356 | SER-692c6133e3f06d96d1751b26e2081a613e5ef4f11bf9096bd0d29d79786a580c | — | **** | — | — | Silverline Clinical Group, Inc. | 8342 | HQ | — | NJ | — | — | — | Beckman Access / DxI | — | — | — | — | — | 11 completed purchases over 861 days; median interval 27.5 days; expected reorder 2026-05-19; High Risk by 83 days. | — | 491.67 | — | — | 185 | — | 70.87 | Low | — | — | — | MANAGER_REVIEW | Candidate CAND-4051d8fb44a0663af05acfcaef46f3e7448036525f64c16678dc09cc3e4bd6ee | Customer 8342 |
| Needs Validation | 234b565c-29e5-43bb-9356-74dd911ab649 | CAND-b22bbff6a9935ea4842b2571373d19c7b0fd4fd96fe7238c35eb38d27b39ce91 | OPP-4478ef97cd63aadb3f12500019ed93e44272fcaf248ce41f24938ff558f305fc | SER-2a8adfc76f78b1c6482c9a7abce9d6bb7e1673bc01d69e85a725a1b7f612d68b | — | **** | — | — | Silverline Clinical Group, Inc. | 8342 | HQ | — | NJ | — | — | — | Olympus / Beckman AU | — | — | — | — | — | 7 completed purchases over 876 days; median interval 59.5 days; expected reorder 2026-05-11; High Risk by 91 days. | — | 158 | — | — | 25 | — | 63.62 | Low | — | — | — | MANAGER_REVIEW | Candidate CAND-b22bbff6a9935ea4842b2571373d19c7b0fd4fd96fe7238c35eb38d27b39ce91 | Customer 8342 |
| Needs Validation | 234b565c-29e5-43bb-9356-74dd911ab649 | CAND-3918fcef18e2203f8a4d6b5e513255c26b5077858b6004ea80e7697d0a47273a | OPP-60a94a62714a0fc311e8b442c0fb47639eb6d4b2b19dcd8ec1307ad5265c2d9a | SER-b09f1c6bd36e2a0f123dd2b67fee589dec3af9583993967cb8fbac2cc7caa53a | — | **** | — | — | Silverline Clinical Group, Inc. | 8342 | HQ | — | NJ | — | — | — | Beckman Access / DxI | — | — | — | — | — | 12 completed purchases over 1067 days; median interval 44.0 days; expected reorder 2026-09-06; Due Soon in 27 days. | — | 1277 | — | — | 178.13 | — | 63.57 | Low | — | — | — | MANAGER_REVIEW | Candidate CAND-3918fcef18e2203f8a4d6b5e513255c26b5077858b6004ea80e7697d0a47273a | Customer 8342 |